Skip to content

Author

H. Gelderblom

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Pimicotinib versus placebo in tenosynovial giant cell tumor (TGCT): a plain language summary of the MANEUVER clinical trial.

What is this summary about?This summary describes the main findings of the MANEUVER clinical trial for pimicotinib, a once-daily treatment. The goal was to see if pimicotinib could significantly reduce tumor size after 24 weeks of treatment in clinical trial participants with tenosynovial giant cell tumor (TGCT) comp...

H. Gelderblom, Xiao-Hui Niu, S. Stacchiotti et al. · 0 citations
Open access Sep 2026

DPYD c.85T>C, DPYD c.496A>G, and DPYD c.2194G>A and severe toxicity to fluoropyrimidines in PREPARE and Alpe-DPD trials. An original study and meta-analysis.

Current DPYD genotyping panels used to prevent fluoropyrimidine (FL)-related toxicity explain only a limited proportion of severe adverse events. The clinical relevance, beyond current testing, of additional DPYD variants, including DPYD⁎6 (c.2194G>A, rs1801160), DPYD c.496A>G (rs2297595), and DPYD⁎9A (c.85T>C, rs18012...

E. De Mattia, J. Polesel, M. van der Lee et al. · 0 citations
Sep 2026

Critical appraisal of combination therapies: the impact of trial design on Benefit-Risk outcomes.

Combination therapies are widely used in oncology due to their potential to improve therapeutic efficacy and overcome drug resistance. However, these potential advantages must be weighed against added toxicity, treatment burden, and costs. In this commentary, we examine some recent examples of divergent opinions by the...

F. de Jong, L. Douma, P. Baas et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.